Granulocyte colony-stimulating factor (G-CSF) is widely used as a neutrophil supportive therapy in breast cancer chemotherapy. Common adverse events of G-CSF include bone pain, headache, and fatigue; however, reports of G-CSF-associated vasculitis are few.
Case report
A 66-year-old woman who had undergone surgery for breast cancer received adjuvant chemotherapy with prophylactic use of pegfilgrastim (peg-G). She developed peg-G-associated vasculitis 11 days after initially receiving peg-G.
Management and outcome: Although various blood and culture tests were required to rule out other vasculitis syndromes and infections, her symptoms spontaneously disappeared without any treatment other than discontinuation of the causal drug.
Discussion
G-CSF-associated vasculitis is occasionally accompanied by severe complications such as aortic dissection and aneurysm formation. This case report is important to draw attention towards this rare and difficult-to-diagnosis adverse event of peg-G.
HolmesFAO’ShaughnessyJAVukeljaS, et al.
Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer.J Clin Oncol2002;
20: 727–731.
2.
VoseJMCrumpMLazarusH, et al.
Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma.J Clin Oncol2003;
21: 514–519.
3.
D’SouzaAJaiyesimiITrainorL, et al.
Granulocyte colony-stimulating factor administration: adverse events.Transfus Med Rev2008;
22: 280–290.
4.
GertzMALacyMQBjornssonJ, et al.
Fatal pulmonary toxicity related to the administration of granulocyte colony-stimulating factor in amyloidosis: a report and review of growth factor induced pulmonary toxicity. J Hematother Stem Cell Res2000;
9: 635–643.
5.
O’MalleyDPWhalenMBanksPM.Spontaneous splenic rupture with fatal outcome following G-CSF administration for myelodysplastic syndrome.Am J Hematol2003;
73: 294–295.
6.
KawachiYWatanabeAUchidaT, et al.
Acute arterial thrombosis due to platelet aggregation in a patient receiving granulocyte colony-stimulating factor.Br J Haematol1996;
94: 413–416.
7.
DarieCBoutalbaSFichterP, et al.
Aortitis after G-CSF injections. Rev Med Interne2004;
25: 225–229 (in French).
8.
OshimaYTakahashiSTaniK, et al.
Granulocyte colony-stimulating factor-associated aortitis in the Japanese Adverse Drug Event Report database.Cytokine2019;
119: 47–51.
9.
AdigaGUElkadiDMalikSK, et al.
Abdominal aortitis after use of granulocyte colony-stimulating factor.Clin Drug Investig2009;
29: 821–825.
10.
MillerEBGrosuRLandauZ.Isolated abdominal aortitis following administration of granulocyte colony stimulating factor (G-CSF).Clin Rheumatol2016;
35: 1655–1657.
11.
UmedaMIkenagaJKogaT, et al.
Giant cell arteritis which developed after the administration of granulocyte-colony stimulating factor for cyclic neutropenia. Intern Med2016;
55: 2291–2294.
12.
SatoYKajiSUedaH, et al.
Thoracic aortitis and aortic dissection following pegfilgrastim administration. Eur J Cardiothorac Surg2017;
52: 993–994.
13.
FukuiSIwamotoNKawakamiA.Drug-induced large vessel vasculitis with carotid arterial ring sign.Scand J Rheumatol2018;
47: 83–84.
14.
ItoYNodaKAibaK, et al.
Diffuse large B-cell lymphoma complicated with drug-induced vasculitis during administration of pegfilgrastim. Rinsho Ketsueki2017;
58: 2238–2242 (in Japanese).
15.
HiranumaKKusunokiSFujinoK, et al.
Drug-induced aortitis in a patient with ovarian cancer treated with bevacizumab combination therapy.Taiwan J Obstet Gynecol2018;
57: 750–752.
16.
ChinoTObaTYamamotoK, et al.
A case of arteritis that developed after pegfilgrastim administration during chemotherapy for breast cancer. Gan To Kagaku Ryoho2018;
45: 1771–1774 (in Japanese).
17.
ParodisIDaniLNotarnicolaA, et al.
G-CSF-induced aortitis: two cases and review of the literature.Autoimmun Rev2019;
18: 615–620.
18.
SasakiKMiyauchiMOguraM, et al.
Arteritis after administration of granulocyte colony-stimulating factor: a case series.Int J Hematol2019;
110: 370–374.
19.
KinjoYKuritaTUedaT, et al.
Acute arteritis after G-CSF administration.Int Cancer Conf J2019;
8: 77–80.
20.
YukawaKMokudaSYoshidaY, et al.
Large-vessel vasculitis associated with PEGylated granulocyte-colony stimulating factor. Neth J Med2019;
77: 224–226.
NaranjoCABustoUSellersEM, et al.
A method for estimating the probability of adverse drug reactions.Clin Pharmacol Ther1981;
30: 239–245.
23.
LysákDHrabětováMVrzalováJ, et al.
Changes of cytokine levels during granulocyte-colony-stimulating factor stem cell mobilization in healthy donors: association with mobilization efficiency and potential predictive significance.Transfusion2011;
51: 319–327.
24.
SondereggerIIezziGMaierR, et al.
GM-CSF mediates autoimmunity by enhancing IL-6-dependent Th17 cell development and survival.J Exp Med2008;
205: 2281–2294.
25.
BiganzoliLCuferTBruningP, et al.
Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: the European Organization for Research and Treatment of Cancer 10961 Multicenter Phase III Trial.J Clin Oncol2002;
20: 3114–3121.
26.
CrawfordJBeckerPSArmitageJO, et al.
Myeloid growth factors, version 2.2017, NCCN clinical practice guidelines in oncology.J Natl Compr Canc Netw2017;
15: 1520–1541.
27.
HanHSReisIMZhaoW, et al.
Racial differences in acute toxicities of neoadjuvant or adjuvant chemotherapy in patients with early-stage breast cancer.Eur J Cancer2011;
47: 2537–2545.
28.
KimCGSohnJChonH, et al.
Incidence of febrile neutropenia in Korean female breast cancer patients receiving preoperative or postoperative doxorubicin/cyclophosphamide followed by docetaxel chemotherapy.J Breast Cancer2016;
19: 76–82.
